7th TPD and Induced Proximity Summit

Accelerating the Discovery, Development & Approval of First-In-Class Selective, Safe & Efficacious Degraders & Proximity-Based Drugs to Target the Undruggable

As the TPD field eagerly awaits the approval of Arvinas’s Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.

Returning as the industry’s definitive forum from early discovery to clinical development, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.

Featuring key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this is your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.